<DOC>
	<DOCNO>NCT00373529</DOCNO>
	<brief_summary>Clolar ( clofarabine injection ) approve Food Drug Administration ( FDA ) treatment pediatric patient 1 21 year old relapse acute lymphoblastic leukemia ( ALL ) least 2 prior treatment regimen . This study evaluate efficacy clofarabine elderly patient acute myelogenous leukemia ( AML ) unlikely benefit treatment intensive chemotherapy regimen ( cytarabine anthracycline base regimen ) use young patient AML .</brief_summary>
	<brief_title>A Study Clofarabine Older Patients With Newly Diagnosed Acute Myelogenous Leukemia ( AML ) ( CLASSIC II )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<criteria>Diagnosis AML ( de novo , secondary antecedent hematologic disorder [ AHD ] ) Age ≥ 60 year Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Presence least one adverse prognostic factor : Age ≥ 70 year ; AHD ; ECOG performance status 2 ; Intermediate unfavorable ( i.e. , adverse ) karyotype define cytogenetic profile except presence following : ( 8 ; 21 ) ( q22 ; q22 ) inv ( 16 ) ( p13 ; q22 ( 16 ; 16 ) ( p13 ; q22 ) ( 15 ; 17 ) ( q22 ; q12 ) variant . Adequate renal hepatic function : Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) ; Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5 x ULN ; Serum creatinine ≤ 1.0 mg/dL ; serum creatinine &gt; 1.0 mg/dL , estimate glomerular filtration rate ( GFR ) must &gt; 60 mL/min/1.73 m^2 calculate Modification Diet Renal Disease ( MDRD ) equation Adequate cardiac function : leave ventricular ejection fraction ( LVEF ) ≥ 40 % leave ventricular fractional shortening ≥ 22 % Diagnosis acute promyelocytic leukemia Prior treatment clofarabine Prior treatment AML antecedent hematologic disorder Prior hematopoietic stem cell transplant ( HSCT ) Prior radiation therapy pelvis Investigational agent receive within 30 day prior first dose study drug Ongoing uncontrolled systemic infection Diagnosis another malignancy , unless patient diseasefree least 5 year follow completion curative intent therapy follow exception : Patients treat nonmelanoma skin cancer , insitu carcinoma cervical intraepithelial neoplasia regardless diseasefree duration eligible study definitive treatment condition complete ; Patients organconfined prostate cancer evidence recurrent progressive disease base PSA value eligible study hormonal therapy initiate radical prostatectomy perform Clinical evidence central nervous system ( CNS ) involvement Severe concurrent medical condition psychiatric disorder would preclude study participation Positive human immunodeficiency virus ( HIV ) test</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Acute myelogenous leukemia</keyword>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>newly Diagnosed AML</keyword>
	<keyword>Clofarabine</keyword>
	<keyword>CLASSIC II</keyword>
	<keyword>CLO243</keyword>
</DOC>